Ayala Pharmaceuticals, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 6th, 2020 Company Industry JurisdictionThis letter agreement is being delivered to you in connection with the proposed underwriting agreement (the “Underwriting Agreement”), among Ayala Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of you as representatives (the “Representatives”) of a group of Underwriters named therein, relating to an underwritten public offering of Common Stock, $0.01 par value (the “Common Stock”), of the Company (the “Offering”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMarch 6th, 2020 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (this “Agreement”), dated as of July 24, 2019 (the “Effective Date”) is by and between Ayala Pharmaceuticals, Inc. (the “Company”), and Gary Gordon (the “Employee”) (individually, each a “Party” and collectively, the “Parties”).
AYALA PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMarch 6th, 2020 Company Industry JurisdictionTHIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of December 19, 2018, by and among Ayala Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each investor listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor, and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder”, and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
ContractLicense Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMarch 6th, 2020 Company Industry JurisdictionCertain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
This is a translation into English of the final Hebrew version of the Lease Agreement. In the event of a conflict between the English and Hebrew texts, the Hebrew text shall prevail. Lease Agreement Made and executed in Tel Aviv on the 24th day of...Ayala Pharmaceuticals, Inc. • March 6th, 2020 • Biological products, (no disgnostic substances)
Company FiledMarch 6th, 2020 Industry
EVALUATION, OPTION AND LICENSE AGREEMENTOption and License Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 6th, 2020 Company Industry JurisdictionCertain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
EMPLOYMENT AGREEMENTEmployment Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 6th, 2020 Company IndustryThis Employment Agreement (this “Agreement”) is entered into effective as of March 15, 2019, by and between Ayala-Oncology Israel Ltd., an Israeli company P.C. No. 51-574869-7 (the “Company”), and Yossi Maimon, Israeli I.D. No. 024821233 (the “Employee”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 6th, 2020 Company IndustryTHIS EMPLOYMENT AGREEMENT (the “Agreement”) is effective as of the Effective Date, by and between Ayala Oncology Israel Ltd., a company organized under the laws of the State of Israel, P.C. No. 51-574869-7 (the “Company”) and Employee.